What the study found
The study found that microbiota dysbiosis, meaning an imbalance in the gut microbial community, and mucosal hyperinnervation, meaning extra nerve growth in the intestinal lining, contributed to intestinal hyperalgesia, or increased pain sensitivity, in a mouse model of postinfectious irritable bowel syndrome. Rifaximin reduced this pain response, and combining rifaximin with a 5-HT 7 receptor antagonist reduced intestinal nociception back to baseline.
Why the authors say this matters
The authors suggest that the model may help represent diverse risk factors for postinfectious irritable bowel syndrome. The findings indicate that targeting both microbial changes and nerve-related signaling may be relevant to reducing intestinal pain.
What the researchers tested
The researchers developed a mouse model of postinfectious irritable bowel syndrome using two triggers: Giardia postinfection and water avoidance stress. They tested rifaximin, a gut-targeted antibiotic, and also examined brain-derived neurotrophic factor (BDNF), a molecule involved in nerve growth, as well as the 5-HT 7 serotonin receptor.
What worked and what didn't
Rifaximin treatment reduced intestinal hyperalgesia and was associated with lower mucosal neurite outgrowth and reduced BDNF expression. BDNF activation caused nerve fiber elongation and increased 5-HT 7 expression through separate signaling pathways, and the combination of rifaximin with a 5-HT 7 receptor antagonist reduced intestinal nociception to baseline. The abstract does not report effects that clearly failed aside from these results.
What to keep in mind
This summary is based on a mouse model, so the findings are limited to that experimental setting. The abstract does not describe sample size, study duration, or additional limitations.
Key points
- A mouse model of postinfectious irritable bowel syndrome was created using Giardia postinfection and water avoidance stress.
- Microbiota dysbiosis and mucosal hyperinnervation were linked to intestinal hyperalgesia in the model.
- Rifaximin reduced intestinal hyperalgesia and was associated with decreased mucosal neurite outgrowth and BDNF expression.
- BDNF activation increased nerve fiber elongation and upregulated 5-HT 7 expression via separate signaling pathways.
- Rifaximin plus a 5-HT 7 receptor antagonist reduced intestinal nociception to baseline.
Disclosure
- Research title:
- Rifaximin reduced intestinal pain in a mouse IBS model
- Authors:
- Li-Yu Lin, Yu‐Hsuan Lin, Chia-Hung Tu, Ming-Shiang Wu, WH Kuo, Chin‐Hung Sun, Ling‐Wei Hsin, Linda Chia‐Hui Yu
- Institutions:
- National Taiwan University, National Taiwan University, National Taiwan University, National Taiwan University, National Taiwan University, National Taiwan University, National Taiwan University Hospital, National Taiwan University Hospital
- Publication date:
- 2026-06-29
- OpenAlex record:
- View
Get the weekly research newsletter
Stay current with scholarly research without reading academic papers — one filtered digest, every Friday.